Gilead Sciences Inc (XTER:GIS)
€ 115.5 +1.62 (+1.42%) Market Cap: 143.59 Bil Enterprise Value: 156.27 Bil PE Ratio: 17.94 PB Ratio: 6.96 GF Score: 82/100

Gilead Sciences Inc at Evercore ISI Healthcare Conference Transcript

Dec 03, 2025 / 03:50PM GMT
Release Date Price: €106.82 (-0.56%)
Umer Raffat
Evercore Inc - Equity Analyst

Thank you guys for joining. Super excited to have Dietmar join us from Gilead. I know we spent time at your prior company as well. So how has the transition been? And how are things going on the West Coast?

Dietmar Berger
Gilead Sciences Inc - Chief Medical Officer

Transition has -- first of all, thanks for having me. Transition has been great. I'm with Gilead since a year. I've always been excited about the science and the people and the impact that Gilead has. And what I found is exactly in line with that. I'm really excited -- it has been going well. We've had good data during the year. Obviously, we have different launches going on. We have the portfolio focus on virology, oncology, and inflam. So it's been a really good year.

Questions & Answers

Umer Raffat
Evercore Inc - Equity Analyst

Fantastic. We're going to focus this conversation today more so on R&D. I know we had Andy with us earlier as well. I was hoping Jacquie would join us, but Jacquie is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot